Measles is far more than a simple childhood rash—it’s a highly contagious viral infection that can lead to serious, even life-threatening complications. While vaccination has made this disease preventable, recent outbreaks remind us how crucial proper medical care and prevention remain for protecting vulnerable populations, especially young children and those unable to receive vaccines.

Managing Measles: More Than Just Waiting It Out

When someone contracts measles, there isn’t a magic pill that can kill the virus directly. The treatment approach centers on helping the body fight the infection while managing symptoms and preventing complications that can turn a serious illness into a life-threatening emergency. The goal is to keep the patient comfortable, well-hydrated, and carefully monitored for any signs that the infection is causing additional problems beyond the characteristic rash and fever.^[1]

Treatment decisions depend heavily on the patient’s age, overall health status, and whether complications develop. Infants under five years old, adults over twenty, pregnant women, and people with weakened immune systems require especially careful attention because they face higher risks of severe outcomes. Each case must be evaluated individually, though certain supportive measures apply to nearly everyone diagnosed with measles.^[1]

Medical professionals emphasize that while there are established, proven methods for managing measles symptoms and complications, ongoing research continues to explore new approaches that might improve outcomes, particularly for those at highest risk. Understanding both current standard treatments and emerging research helps families make informed decisions when measles strikes their community.

Standard Medical Care for Measles Infection

The foundation of measles treatment rests on what doctors call supportive care—medical interventions that help the body’s natural defenses do their work. This isn’t passive waiting; it’s active management of symptoms to prevent the patient from becoming dangerously dehydrated or developing secondary infections that can be far more deadly than the virus itself.^[8]

Maintaining proper hydration stands as perhaps the most critical element of supportive care. Measles causes high fevers that can spike above 104°F (40°C), and these fevers combined with the body’s immune response cause significant fluid loss. Patients must drink plenty of water, broth, or special rehydration solutions that replace not just fluids but also essential minerals called electrolytes that the body needs to function properly. When dehydration becomes severe—particularly in young children who may refuse to drink or who are vomiting—intravenous fluids delivered through a needle in the vein become necessary. This typically requires hospitalization.^[8][11]

Managing fever represents another crucial aspect of care. Healthcare providers recommend medications like acetaminophen (Tylenol) or ibuprofen to reduce fever and ease the body aches and headaches that accompany measles. However, one medication must never be given: aspirin. Children and teenagers with viral illnesses who take aspirin face risk of developing Reye syndrome, a rare but potentially fatal condition that causes severe liver and brain damage. This warning applies to all viral infections, not just measles.^[8][12]

Rest plays a vital but often underestimated role in recovery. The immune system works most effectively when the body isn’t expending energy on other activities. Patients should stay home from school, work, or childcare—not only to rest but also to prevent spreading the extremely contagious virus to others. The eyes often become very sensitive to light during measles infection, so keeping the room dimly lit can provide relief. Complete recovery typically takes about ten days from when the rash first appears, though the cough and fatigue may linger longer.^[2][12]

Vitamin A Supplementation: A Life-Saving Intervention

One specific treatment has proven remarkably effective at reducing measles complications and deaths: vitamin A supplementation. This vitamin plays essential roles in maintaining healthy immune function and protecting the eyes and other tissues. Measles infection depletes the body’s vitamin A stores, and this deficiency contributes directly to severe complications including blindness and death.^[11]

Research has demonstrated that vitamin A supplements reduce measles-related deaths by approximately 50% and help prevent eye damage and blindness. Because of this powerful protective effect, the World Health Organization recommends that all children diagnosed with measles receive vitamin A supplementation, regardless of which country they live in or their apparent nutritional status.^[11]

The dosing schedule depends on the child’s age. Infants younger than six months receive 50,000 international units (IU) daily by mouth for two doses. Children aged six to eleven months receive 100,000 IU daily for two doses. Those older than one year receive 200,000 IU daily for two doses. Children showing clinical signs of vitamin A deficiency receive a third age-appropriate dose given two to four weeks after the first two doses.^[11]

Managing Complications When They Arise

Approximately one in twenty people with measles develops pneumonia—an infection of the lungs that becomes the leading cause of measles-related deaths in young children. Pneumonia may be caused directly by the measles virus itself or by secondary bacterial infections that take advantage of the weakened immune system. When bacterial pneumonia develops, doctors prescribe antibiotics—medications that kill bacteria but have no effect on viruses. Choosing the right antibiotic depends on which bacteria are causing the infection.^[1][9]

Bacterial infections commonly complicate measles in other ways as well. About one in ten children develops otitis media, an ear infection that causes pain and can lead to hearing loss if untreated. Bacteria can also cause throat infections (tonsillitis) or inflammation of the airways. All of these bacterial complications require antibiotic treatment matched to the specific bacteria involved.^[1]

Children with severe complications often need hospitalization for closer monitoring and more intensive supportive care. Those struggling to breathe may require supplemental oxygen delivered through a mask or nasal tubes. In the most severe cases, patients may need a ventilator—a machine that helps them breathe when their lungs can no longer do the work effectively on their own. The medical team will provide intravenous fluids, carefully monitor vital signs, and watch closely for new complications developing.^[10]

Isolation Protocols to Protect Others

Because measles spreads so easily through the air, infected patients must be isolated from others to prevent transmission. Healthcare facilities follow strict airborne precautions when caring for measles patients. These measures include placing the patient in a special negative-pressure room where air flows inward rather than escaping into hallways, and healthcare workers must wear specialized masks called N95 respirators that filter out tiny viral particles.^[1]

Patients remain contagious from four days before the rash appears until four days after the rash emerges. During this entire period, they should stay isolated from others—particularly from pregnant women, infants, and people with weakened immune systems who face the highest risks from measles infection. People with compromised immune systems may remain contagious for longer periods, sometimes throughout their entire illness, and require extended isolation.^[1][12]

Post-Exposure Prevention Strategies

When someone without immunity gets exposed to measles, healthcare providers can sometimes prevent the infection from taking hold or at least reduce its severity. The effectiveness of these interventions depends on how quickly they’re administered after exposure.^[11]

For people older than six months who aren’t immune and are exposed to measles, receiving the MMR vaccine (which protects against measles, mumps, and rubella) within three days of exposure can prevent the infection or significantly reduce its severity. After receiving this post-exposure vaccine, the person doesn’t need to quarantine at home because the vaccine provides protection.^[8][11]

For infants up to eleven months old who are exposed and haven’t received the vaccine, doctors may give a shot of immune globulin—a preparation containing antibodies collected from many blood donors. These antibodies provide temporary, borrowed immunity that can prevent measles or make the illness milder if it does develop. Immune globulin works if given within six days of exposure. After this treatment, the infant must stay quarantined at home for 21 days because protection isn’t guaranteed and the child could still become infectious.^[8][11]

For pregnant women exposed to measles—a particularly dangerous situation since measles during pregnancy can cause miscarriage, premature birth, low birth weight, and life-threatening complications for the mother—immune globulin given to the mother may help. If the infant is born with congenital measles (measles infection acquired before birth), providing immune globulin to the newborn may prevent or reduce the severity of the infection and lower the risk of death.^[1]

Investigational Approaches in Clinical Research

While no antiviral drugs are currently approved specifically for treating measles, researchers continue investigating whether certain medications might help, particularly for severely ill patients or those with weakened immune systems who face the highest risk of death from measles complications.

Ribavirin: An Experimental Antiviral

Ribavirin is an antiviral medication originally developed to treat other viral infections. Laboratory studies have shown that measles virus is susceptible to ribavirin when tested in cell cultures grown in the lab. This finding prompted researchers to explore whether ribavirin might help patients with severe measles infections or the rare but fatal complication called subacute sclerosing panencephalitis (SSPE)—a degenerative brain disease that can develop seven to ten years after measles infection.^[11]

Ribavirin can be administered intravenously (through a vein) or as an aerosol that patients breathe in. Some doctors have used ribavirin to treat severely affected patients or those with weakened immune systems, as well as individuals who developed SSPE or another brain complication called measles inclusion body encephalitis (MIBE). However, no controlled clinical trials have been conducted to rigorously test whether ribavirin actually improves outcomes in measles patients.^[11]

The United States Food and Drug Administration has not approved ribavirin for treating measles, which means using it for this purpose is considered experimental. Doctors who choose to try ribavirin in desperate cases do so based on the laboratory evidence and theoretical benefit, but without solid proof from human studies that it works. Ribavirin also carries risks of side effects, including anemia and other blood disorders, which must be weighed against potential benefits.

Clinical research in this area remains limited. Because measles has become relatively rare in countries with strong medical research infrastructure, conducting large trials to test antiviral treatments has proven challenging. Most measles cases occur in regions with fewer resources for conducting complex clinical studies. Additionally, ethical considerations arise when trying to test new treatments for a disease that already has known effective preventive measures through vaccination.

Research Gaps and Future Directions

The scientific community recognizes several areas where improved treatments could make meaningful differences in measles outcomes. People with compromised immune systems—such as those with HIV infection, leukemia, or those taking medications that suppress immunity—face particularly high death rates from measles because their bodies cannot mount effective immune responses. These patients desperately need treatments beyond supportive care, yet research specifically targeting this population remains sparse.

Brain complications from measles, including acute encephalitis (brain inflammation that occurs during the acute illness) and the delayed SSPE, represent another area where current treatments remain inadequate. Acute encephalitis affects about one in every thousand measles cases and frequently causes permanent brain damage or death. SSPE, though rare, is invariably fatal once symptoms appear. Research exploring ways to protect the brain during measles infection or prevent these neurological complications could save lives and prevent lifelong disability.

Some researchers are investigating whether combining existing antiviral medications with immune-modulating therapies might offer benefits. Others are exploring whether therapeutic antibodies—similar to those used for other viral infections—could be developed specifically to target measles virus. These approaches remain in early research stages and aren’t yet being tested in human clinical trials.

Most common treatment methods

• Supportive care and symptom management
  • Rest at home with isolation from others, particularly during the contagious period from four days before until four days after the rash appears
  • Increased fluid intake with water, broth, or rehydration solutions to prevent dehydration from high fevers
  • Intravenous fluids administered in healthcare facilities when oral hydration isn’t sufficient or when patients cannot drink adequately
  • Fever reduction with acetaminophen (Tylenol) or ibuprofen; aspirin must never be given to children or teenagers due to risk of Reye syndrome
  • Dimming lights to reduce discomfort from light sensitivity affecting the eyes
  • Close monitoring for development of complications requiring more intensive medical intervention
• Vitamin A supplementation
  • Age-appropriate doses given by mouth under medical supervision: 50,000 IU daily for two doses in infants under six months; 100,000 IU daily for two doses in children age six to eleven months; 200,000 IU daily for two doses in children over one year
  • Third dose given two to four weeks later for children showing clinical signs of vitamin A deficiency
  • Reduces measles-related deaths by approximately 50% and helps prevent eye damage and blindness
  • Recommended by the World Health Organization for all children diagnosed with measles regardless of country or apparent nutritional status
• Treatment of bacterial complications
  • Antibiotics for secondary bacterial infections including ear infections (otitis media), throat infections (tonsillitis), and bacterial pneumonia
  • Specific antibiotic choice depends on which bacteria are causing the complication
  • Hospitalization may be required for severe bacterial pneumonia with intravenous antibiotic administration and oxygen support
• Post-exposure prevention
  • MMR vaccine given within three days of exposure to prevent infection or reduce severity in people older than six months who lack immunity; no quarantine required after this intervention
  • Immune globulin given within six days of exposure to infants up to eleven months old who are exposed and not previously vaccinated; requires 21-day quarantine after administration
  • Immune globulin may be given to pregnant women exposed to measles and to newborns with congenital measles to prevent or reduce severity
• Experimental antiviral therapy
  • Ribavirin administered intravenously or as aerosol has been used in some severely affected patients, those with compromised immune systems, and those with brain complications
  • Not approved by regulatory agencies for measles treatment; use is considered experimental
  • No controlled clinical trials have proven effectiveness in human patients